+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating TQB2102 for injection, a new antibody-coupled drug that targets two different parts of the HER2 protein on tumor cells. This study focuses on patients with unresectable locally advanced, recurrent, or metastatic HER2-positive gastroesophageal adenocarcinoma. The trial aims to assess the effectiveness and safety of TQB2102 combined with benmelstobart or penpulimab, with or without chemotherapy, in this patient group. This is a Phase II randomized study sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Participants receive TQB2102 for injection and either benmelstobart or penpulimab, both given intravenously every three weeks. Chemotherapy is taken orally from Day 1 to Day 15 in each 21-day treatment cycle. There are three study groups, each involving different combinations and doses of TQB2102, benmelstobart, penpulimab, and chemotherapy. Treatment continues through multiple cycles as determined by the study protocol. During the study, participants undergo regular assessments including scans and tests to measure tumor response and disease progression. Researchers monitor outcomes like the objective response rate, progression-free survival, duration of response, overall survival, and any adverse events. The study includes follow-up periods to track safety and effectiveness, with an average observation of up to three years. Participants are closely monitored throughout the treatment and follow-up phases for their health and response to therapy.

Age: 18Years - 75YearsAll GendersPhase 2
39 locations
E

Actively Recruiting

Researchers are investigating the effect of baxdrostat, a drug taken once daily, compared to a placebo on lowering 24-hour average systolic blood pressure SBP in adults with uncontrolled hypertension. This condition means their blood pressure remains high despite using two or more antihypertensive medications from different classes without diuretics. The study is a Phase IIIb, randomized, double-blind, placebo-controlled trial conducted across multiple centers in China. Participants will first go through a screening period lasting up to 4 weeks, followed by a 4-week run-in phase where they take a placebo. After this, they will be randomly assigned to receive either baxdrostat 2 mg or placebo orally once daily for 12 weeks while continuing their background blood pressure medications without dose changes, except in cases of low blood pressure symptoms. Rescue therapy is allowed if blood pressure becomes dangerously high, excluding certain diuretics. After treatment, a 2-week safety follow-up will be conducted. The total participation time is approximately 22 weeks. During the study, participants will have their blood pressure monitored, including ambulatory 24-hour average SBP as the primary outcome at week 12. Other assessments include nighttime and daytime blood pressure, seated blood pressure, and safety monitoring for adverse events, including special focus on potassium and sodium levels. Adherence to medication will be tracked, and safety will be overseen by a dedicated committee. Participants health status will be followed through the end of the study period.

Age: 18Years +All GendersPhase 3
51 locations
E

Actively Recruiting

Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.

Age: 18Years +All GendersPhase 3
257 locations
C

Actively Recruiting

Researchers are establishing a standardized clinical database for patients with liver cancer, including hepatocellular carcinoma and related types, to support high-quality real-world clinical studies. This observational study is led by the Department of Hepatobiliary Surgery at the First Affiliated Hospital of the University of Science and Technology of China USTC in collaboration with multiple centers nationwide. The purpose is to collect detailed clinical information to better understand liver cancer outcomes over time. Participants will receive routine clinical treatments for liver cancer, such as surgical resection, ablation, transarterial chemoembolization TACE, hepatic arterial infusion chemotherapy HAIC, and various anti-tumor drugs including immunologic, targeted, and chemotherapy agents. The study observes and records these standard treatments without assigning interventions. The research will track these patients in a cohort database to monitor their treatment and progression. During the study, participants will be followed for up to 10 years to assess overall survival, recurrence-free survival, and survival time after cancer recurrence. Researchers will collect blood and surgical tissue samples and perform regular follow-up visits to gather clinical data and pathology results. This long-term monitoring aims to provide comprehensive insights into liver cancer progression and treatment outcomes.

Age: 18Years +All Genders
38 locations
P

Actively Recruiting

This research aims to evaluate the safety and effectiveness of TQA2225AP025, a recombinant human FGF21-Fc fusion protein, in adults with Non-Alcoholic Steatohepatitis NASH. It is a randomized, double-blind, placebo-controlled Phase II study designed to assess how well two different doses of this treatment work in managing NASH, a liver condition characterized by fat buildup and inflammation. Participants will receive either 25mg or 50mg of TQA2225AP025 or a matching placebo, given by weekly subcutaneous injections for 48 weeks. The study includes two experimental groups receiving the different doses, and all treatments are administered under blinded conditions to assess the treatment effects accurately. During the study, participants will undergo liver biopsies at the start and after 48 weeks to measure changes in liver condition using the NASH CRN scoring system. Safety will be closely monitored by tracking any adverse events throughout the treatment period. The study is expected to provide detailed information on both the treatment impact on liver health and its safety profile over nearly a year of participation.

Age: 18Years - 75YearsAll GendersPhase 2
53 locations
A

Actively Recruiting

Researchers are evaluating intra-arterial thrombolysis as a treatment for adults who have an acute ischemic stroke caused by medium vessel occlusion MeVO or severe artery narrowing. This trial aims to determine the safety and effectiveness of this treatment compared to standard medical care alone. The study addresses the current lack of strong evidence supporting intra-arterial thrombolysis in this specific type of stroke, building on previous trials that showed no clear benefit of endovascular therapy for MeVO. Participants will be randomly assigned to one of two groups. One group will receive the best medical treatment along with intra-arterial thrombolysis using Tenecteplase rhTNK-tPA, administered directly into the artery near the blockage for 5 to 30 minutes. The other group will receive the best medical treatment alone as recommended by stroke care guidelines. The decision to continue thrombolysis beyond the initial 5 minutes is guided by imaging during the procedure. Throughout the study, participants will be monitored for recovery and safety outcomes. The primary measure will be the level of disability 90 days after treatment, using the modified Rankin Scale. Additional assessments include neurological improvements or deterioration within 24 hours and overall functional independence. The trial is designed to carefully track patient progress and adverse events to evaluate the treatments impact over time.

Age: 18Years +All GendersPhase Not Applicable
6 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of BHV-3000 rimegepant compared to a placebo for treating moderate or severe migraine attacks in children and adolescents aged 6 to under 18 years. This Phase 3 study focuses on acute treatment for pediatric migraine, including cases with or without aura, aiming to better understand how well rimegepant relieves migraine pain and associated symptoms shortly after dosing. Participants are randomly assigned to receive either BHV-3000 at doses of 75 mg or 50 mg orally disintegrating tablet ODT or a matching placebo tablet. The study uses a triple-blind design to compare outcomes between these groups. The trial includes children and adolescents who experience 1 to 8 moderate or severe migraine attacks monthly, with attacks lasting over 3 hours. Some participants may continue stable preventive migraine medications except CGRP antagonists. The study monitors patients during the acute migraine attack treatment phase. During the study, participants will be assessed for pain freedom two hours after dosing as the primary outcome, as well as secondary outcomes such as freedom from the most bothersome migraine symptoms, need for rescue medication within 24 to 48 hours, sustained pain freedom, and ability to function normally. Safety and efficacy data will be collected throughout. The total duration of participation varies depending on individual treatment and follow-up requirements, with the primary completion planned by January 2029.

Age: 6Years - 17YearsAll GendersPhase 3
246 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of atorvastatin in adults aged 18 to 80 years who have experienced spontaneous intracerebral hemorrhage ICH within 3 to 24 hours of symptom onset. This multicenter, prospective, randomized, open-label, blinded end-point PROBE study aims to determine if atorvastatin improves clinical outcomes compared to best medical treatment alone. The study focuses on patients with hematomas located in the supratentorial region and uses the modified Rankin Scale mRS to measure functional outcomes at 90 days. Participants will be randomly assigned to one of two groups one group will receive atorvastatin 20 mg once daily for 21 days along with best medical treatment BMT following current guidelines for ICH, while the other group will receive only BMT. The treatment period lasts for 21 days starting within 48 hours of symptom onset or last known well time. The study will monitor changes in hematoma and perihematomal edema volumes at specific time points during the first week after hemorrhage. During the trial, participants will undergo assessments including computed tomography CT scans to confirm ICH diagnosis and measure hematoma size, as well as evaluations using the Glasgow Coma Scale and mRS. Researchers will track functional independence and neurological outcomes at 90 7 days. Safety and adverse events will be monitored throughout the study. The total follow-up includes primary and secondary outcome measurements up to three months after treatment to evaluate the impact of atorvastatin on recovery.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
22 locations
E

Actively Recruiting

Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of TQC2731 injection in adults with severe asthma that is not adequately controlled. The study aims to compare TQC2731 with a placebo to better understand its impact on asthma exacerbations and other clinical outcomes in this population. Participants are randomly assigned in a 11 ratio to receive either TQC2731 injection or placebo via subcutaneous injection every 4 weeks. Treatment cycles last 4 weeks each, with study drug administration continuing from Day 0 up to Week 48. The trial includes two groups one receiving the active drug and the other receiving placebo, both with the same dosing schedule. During the study, participants will be monitored for asthma exacerbations, lung function through forced expiratory volume in 1 second FEV1, asthma control questionnaires, quality of life assessments, symptom diaries, and biomarker changes such as blood eosinophils and immunoglobulin E levels. Safety assessments include monitoring for anti-drug antibodies and neutralizing antibodies. The primary outcome is the annualized incidence of asthma exacerbations from the first day of dosing through 52 weeks. Secondary outcomes and safety follow-up extend up to Week 64.

Age: 18Years - 75YearsAll GendersPhase 3
101 locations